Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:60081 |
Name | triple-receptor negative breast cancer |
Definition | A breast cancer that is characterized by the absence of estrogen, progresterone and Her2 receptors. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer triple-receptor negative breast cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PTEN loss | AZD8186 | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PTEN loss | AZD6482 + Talazoparib | triple-receptor negative breast cancer | sensitive | detail... |
PTEN loss | AZD6482 + Niraparib | triple-receptor negative breast cancer | sensitive | detail... |
PTEN loss | AZD6482 + Olaparib | triple-receptor negative breast cancer | sensitive | detail... |
PTEN loss | AZD6482 + Rucaparib | triple-receptor negative breast cancer | sensitive | detail... |
PTEN loss | AZD6482 + Veliparib | triple-receptor negative breast cancer | sensitive | detail... |
PIK3CA mutant | Palbociclib + Pictilisib | triple-receptor negative breast cancer | sensitive | detail... |
PIK3CA wild-type | Palbociclib + Pictilisib | triple-receptor negative breast cancer | no benefit | detail... |
PTEN loss RB1 loss | Palbociclib + Pictilisib | triple-receptor negative breast cancer | no benefit | detail... |
PTEN loss RB1 loss | Pictilisib | triple-receptor negative breast cancer | resistant | detail... |
PTEN loss RB1 loss | Palbociclib | triple-receptor negative breast cancer | resistant | detail... |
JAK2 over exp | NVP-BSK805 + Paclitaxel | triple-receptor negative breast cancer | sensitive | detail... |
JAK2 amp | NVP-BSK805 + Paclitaxel | triple-receptor negative breast cancer | sensitive | detail... |
JAK2 amp | NVP-BSK805 | triple-receptor negative breast cancer | sensitive | detail... |
TP53 R280K | YW3-56 | triple-receptor negative breast cancer | sensitive | detail... |
PIK3CA mutant | Pictilisib | triple-receptor negative breast cancer | sensitive | detail... |
PIK3CA amp | Linsitinib + Pictilisib | triple-receptor negative breast cancer | sensitive | detail... |
PIK3CA amp | NVP-AEW541 + Pictilisib | triple-receptor negative breast cancer | sensitive | detail... |
TP53 mutant | Carboplatin + Nutlin-3a | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PIK3CA H1047R PTEN loss | ABT-737 + Dactolisib | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PIK3CA H1047R PTEN loss | ABT-737 + Sapanisertib | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PTEN loss | M2698 | triple-receptor negative breast cancer | sensitive | detail... |
PTEN A72fs | DHM25 | triple-receptor negative breast cancer | sensitive | detail... |
PTEN V275* | DHM25 | triple-receptor negative breast cancer | sensitive | detail... |
PIK3CA act mut | Bevacizumab + Doxorubicin + Everolimus | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PIK3CA act mut | Bevacizumab + Doxorubicin + Temsirolimus | triple-receptor negative breast cancer | predicted - sensitive | detail... |
TP53 mutant | Doxorubicin + Seliciclib | triple-receptor negative breast cancer | predicted - sensitive | detail... |
TP53 mutant | GDC-0425 + Gemcitabine | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PTEN dec exp | Ipatasertib + Paclitaxel | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PTEN inact mut | Capivasertib + Paclitaxel | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PTEN dec exp | Docetaxel + Ipatasertib | triple-receptor negative breast cancer | sensitive | detail... |
PTEN dec exp | Ipatasertib | triple-receptor negative breast cancer | sensitive | detail... |
PIK3CA act mut | Capivasertib + Paclitaxel | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PTEN loss | Capivasertib + Paclitaxel | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PIK3CA act mut | Ipatasertib + Paclitaxel | triple-receptor negative breast cancer | no benefit | detail... |
PTEN inact mut | Ipatasertib + Paclitaxel | triple-receptor negative breast cancer | no benefit | detail... |
FGFR2 positive | Alofanib | triple-receptor negative breast cancer | sensitive | detail... |
BRAF V600E | Nab-paclitaxel + Vemurafenib | triple-receptor negative breast cancer | predicted - sensitive | detail... |
FGFR1 amp | Lucitanib | triple-receptor negative breast cancer | predicted - sensitive | detail... |
FGFR1 amp | Rogaratinib | triple-receptor negative breast cancer | no benefit | detail... |
FGFR2 amp | Futibatinib | triple-receptor negative breast cancer | predicted - sensitive | detail... |
FGFR2 amp | 3D185 | triple-receptor negative breast cancer | sensitive | detail... |
PTEN dec exp | Alpelisib + Everolimus | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PIK3CA amp PTEN H123P | Alpelisib + Everolimus | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PIK3CA amp PTEN H123P | Afatinib + Alpelisib | triple-receptor negative breast cancer | predicted - sensitive | detail... |
RAD51D V200* | Olaparib | triple-receptor negative breast cancer | sensitive | detail... |
RAD51D K91fs | Olaparib | triple-receptor negative breast cancer | sensitive | detail... |
FGFR2 Y375C FGFR2 amp | Futibatinib | triple-receptor negative breast cancer | sensitive | detail... |
FGFR2 Y375C FGFR2 amp | Pemigatinib | triple-receptor negative breast cancer | sensitive | detail... |
BRAF G464V | SIJ777 | triple-receptor negative breast cancer | sensitive | detail... |
ATM loss | Ceralasertib + Olaparib | triple-receptor negative breast cancer | predicted - sensitive | detail... |
BRAF V600E | Vemurafenib | triple-receptor negative breast cancer | predicted - sensitive | detail... |
BRAF V600E | Dabrafenib | triple-receptor negative breast cancer | sensitive | detail... |
BRAF V600E | Trametinib | triple-receptor negative breast cancer | sensitive | detail... |
BRAF V600E | Binimetinib | triple-receptor negative breast cancer | sensitive | detail... |
FGFR2 C382R | Erdafitinib | triple-receptor negative breast cancer | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00576654 | Phase I | Irinotecan Veliparib | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT00740805 | Phase I | Aldoxorubicin + Cyclophosphamide + Veliparib | Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT01116648 | Phase Ib/II | Olaparib Cediranib + Olaparib | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT01351103 | Phase I | LGK974 LGK974 + Spartalizumab | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Completed | USA | NLD | ITA | FRA | ESP | DEU | CAN | 0 |
NCT01391143 | Phase I | MGA271 | Safety Study of MGA271 in Refractory Cancer | Completed | USA | 0 |
NCT01562873 | Phase II | Ruxolitinib | Ruxolitinib in Patients With Breast Cancer | Terminated | USA | 0 |
NCT01587703 | Phase I | Molibresib | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | Completed | USA | NLD | GBR | FRA | ESP | AUS | 1 |
NCT01623349 | Phase I | Alpelisib + Olaparib Buparlisib + Olaparib | Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer | Completed | USA | 0 |
NCT01639248 | Phase II | ENMD-2076 | Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC | Completed | USA | 1 |
NCT01653470 | Phase I | Carboplatin Fluorouracil + Irinotecan + Leucovorin BMS-906024 Paclitaxel | Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors | Completed | USA | CAN | BEL | 0 |
NCT01695005 | Phase I | LY3039478 | A Study of LY3039478 in Participants With Advanced Cancer | Completed | USA | GBR | FRA | ESP | DNK | DEU | 0 |
NCT01884285 | Phase I | AZD8186 Abiraterone + AZD8186 AZD8186 + Vistusertib | AZD8186 First Time In Patient Ascending Dose Study | Completed | USA | GBR | ESP | CAN | 0 |
NCT01920061 | Phase I | Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib | A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) | Completed | USA | ITA | GBR | ESP | CAN | 0 |
NCT01928394 | Phase Ib/II | Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ITA | GBR | FIN | ESP | DNK | DEU | CAN | 0 |
NCT01931163 | Phase II | Everolimus | NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer | Completed | USA | 0 |
NCT01938638 | Phase I | BAY1143572 | Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer | Completed | USA | 3 |
NCT01969643 | Phase I | Ladiratuzumab vedotin Ladiratuzumab vedotin + Trastuzumab | A Safety Study of SGN-LIV1A in Breast Cancer Patients | Completed | USA | 0 |
NCT01982448 | Phase II | Paclitaxel Cisplatin | Cisplatin vs Paclitaxel for Triple Negative Breast Cancer | Completed | USA | 0 |
NCT01990209 | Phase II | Orteronel | Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) | Completed | USA | 0 |
NCT01997333 | Phase II | Glembatumumab vedotin Capecitabine | Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 0 |
NCT01999738 | Phase I | EC1456 | Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02000882 | Phase II | Buparlisib + Capecitabine | Capecitabine + BKM120 TNBC BC Brain Met | Completed | USA | 0 |
NCT02003092 | Phase I | RX-5902 | RX-5902 Treatment of Subjects With Solid Tumors | Terminated | USA | 0 |
NCT02014337 | Phase I | Eribulin + Mifepristone | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | Completed | USA | 0 |
NCT02032823 | Phase III | Olaparib | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA) | Active, not recruiting | USA | SWE | POL | NLD | ITA | ISR | ISL | HUN | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUT | AUS | ARG | 6 |
NCT02071862 | Phase I | Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | Completed | USA | 0 |
NCT02078752 | Phase I | PF-06647263 | A Study Of PF-06647263 In Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02101385 | Phase II | Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer | Completed | USA | 0 | |
NCT02120469 | Phase I | Eribulin + Everolimus | Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer | Completed | USA | 0 |
NCT02138812 | Phase I | BAY1161909 + Paclitaxel | Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel | Terminated | USA | 0 |
NCT02157792 | Phase I | Berzosertib + Irinotecan Berzosertib + Cisplatin + Gemcitabine Berzosertib + Cisplatin + Etoposide Berzosertib + Cisplatin Berzosertib + Carboplatin + Cisplatin Berzosertib + Gemcitabine | M6620 First in Human Study | Completed | USA | GBR | 0 |
NCT02158507 | Phase I | Lapatinib + Veliparib | Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02162719 | Phase II | Ipatasertib + Paclitaxel Paclitaxel | A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer | Completed | USA | ITA | FRA | ESP | BEL | 3 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02187991 | Phase II | Paclitaxel Alisertib + Paclitaxel | Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer | Completed | USA | 0 |
NCT02203513 | Phase II | Prexasertib | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer | Terminated | USA | 0 |
NCT02208375 | Phase Ib/II | Capivasertib + Olaparib Olaparib + Vistusertib | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | Active, not recruiting | USA | 0 |
NCT02222922 | Phase I | Avelumab + Cofetuzumab pelidotin Fluconazole Cofetuzumab pelidotin | A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors | Completed | USA | ESP | 0 |
NCT02264678 | Phase Ib/II | Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib | Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents | Recruiting | USA | HUN | GBR | FRA | ESP | CAN | BEL | AUS | 1 |
NCT02276443 | Phase 0 | Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative | Recruiting | USA | 0 | |
NCT02281409 | Phase Ib/II | Mogamulizumab | Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors | Completed | USA | 0 |
NCT02299635 | Phase II | Nirogacestat | A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations | Terminated | USA | POL | ITA | HUN | GBR | ESP | 0 |
NCT02307240 | Phase I | CUDC-907 | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | Completed | USA | 0 |
NCT02322814 | Phase II | Cobimetinib + Paclitaxel Paclitaxel Atezolizumab + Cobimetinib + Paclitaxel Atezolizumab + Cobimetinib + Nab-paclitaxel | A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread | Terminated | USA | ROU | LVA | ITA | ISR | GBR | FRA | ESP | CZE | BEL | AUS | 2 |
NCT02358200 | Phase I | Carboplatin + Paclitaxel + Talazoparib | Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer | Terminated | USA | 0 |
NCT02365662 | Phase I | ABBV-221 | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor | Terminated | USA | ESP | 0 |
NCT02366949 | Phase I | BAY1217389 + Paclitaxel Paclitaxel | Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel | Completed | USA | NLD | 0 |
NCT02368691 | Phase II | Enobosarm | Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) | Terminated | USA | 0 |
NCT02370238 | Phase II | Reparixin | A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer | Completed | USA | POL | ITA | FRA | ESP | CZE | BEL | 0 |
NCT02375958 | Phase I | PCA062 | PCA062 in pCAD-positive Tumors. | Completed | USA | ITA | FRA | ESP | 2 |
NCT02393794 | Phase Ib/II | Cisplatin + Nivolumab + Romidepsin Cisplatin + Romidepsin | Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | Active, not recruiting | USA | 0 |
NCT02401347 | Phase II | Talazoparib | Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors | Completed | USA | 0 |
NCT02411656 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy | Active, not recruiting | USA | 0 |
NCT02419417 | Phase Ib/II | BMS986158 Paclitaxel | Study of BMS-986158 in Subjects With Select Advanced Solid Tumors | Completed | USA | FRA | ESP | CAN | AUS | 0 |
NCT02425891 | Phase III | Atezolizumab + Nab-paclitaxel Nab-paclitaxel | A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) | Completed | USA | TUR | SWE | SVN | ROU | POL | NOR | LVA | ITA | HUN | GRC | GBR | FRA | FIN | EST | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 15 |
NCT02427581 | Phase I | Poly ICLC | Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | Withdrawn | 0 | |
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT02435680 | Phase II | MCS110 Carboplatin + Gemcitabine | Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) | Completed | USA | TUR | ITA | FRA | ESP | DEU | BEL | AUT | AUS | 3 |
NCT02447003 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086) | Completed | 0 | |
NCT02452424 | Phase Ib/II | Pembrolizumab + Pexidartinib | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | Terminated | USA | 0 |
NCT02456857 | Phase II | Bevacizumab Everolimus Pegylated liposomal doxorubicin | Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative | Completed | USA | 0 |
NCT02457910 | Phase Ib/II | Enzalutamide Enzalutamide + Taselisib | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer | Terminated | USA | 0 |
NCT02471846 | Phase I | Navoximod Atezolizumab | A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 1 |
NCT02474173 | Phase I | Paclitaxel Onalespib | Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer | Terminated | USA | 0 |
NCT02489448 | Phase Ib/II | Durvalumab + Nab-paclitaxel Cyclophosphamide + Doxorubicin | Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer | Completed | USA | 0 |
NCT02498613 | Phase II | Cediranib + Olaparib | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT02513472 | Phase Ib/II | Eribulin + Pembrolizumab | Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (ENHANCE-1) | Completed | USA | 0 |
NCT02528357 | Phase I | GSK3174998 Pembrolizumab | GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors | Completed | USA | NLD | FRA | CAN | 0 |
NCT02530489 | Phase II | Atezolizumab + Nab-paclitaxel | Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02531932 | Phase II | Carboplatin Everolimus | Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02540291 | Phase I | E7046 | Study of E7046 in Subjects With Selected Advanced Malignancies | Terminated | USA | FRA | 0 |
NCT02543645 | Phase Ib/II | Atezolizumab + Varlilumab | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Terminated | USA | 0 |
NCT02554812 | Phase Ib/II | Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | Terminated | USA | POL | GBR | FRA | CAN | AUS | 2 |
NCT02555657 | Phase III | Pembrolizumab Eribulin Gemcitabine Vinorelbine Capecitabine | Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) | Completed | 0 | |
NCT02559492 | Phase I | Epacadostat + Itacitinib Itacitinib + Parsaclisib | INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors | Terminated | USA | 0 |
NCT02574455 | Phase III | Sacituzumab govitecan-hziy Capecitabine + Eribulin + Gemcitabine + Vinorelbine | ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer (ASCENT) | Completed | USA | GBR | FRA | ESP | DEU | CAN | BEL | 0 |
NCT02575781 | Phase I | SAR428926 | A Study of SAR428926 in Patients With Advanced Solid Tumors | Completed | FRA | ESP | DNK | 0 |
NCT02580448 | Phase Ib/II | Seviteronel | A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer | Completed | USA | 0 |
NCT02593175 | Phase II | Carboplatin + Paclitaxel + Panitumumab | Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC | Active, not recruiting | USA | 0 |
NCT02624700 | Phase II | Pemetrexed Disodium + Sorafenib | Study of Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer | Terminated | USA | 0 |
NCT02627430 | Phase I | Onalespib + Talazoparib | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | Withdrawn | 0 | |
NCT02628535 | Phase I | Obrindatamab | Safety Study of MGD009 in B7-H3-expressing Tumors | Terminated | USA | CAN | AUS | 0 |
NCT02630368 | Phase Ib/II | Avelumab + Cyclophosphamide + JX-594 Cyclophosphamide + JX-594 Cyclophosphamide | A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) (METROmaJX) | Unknown status | FRA | 0 |
NCT02632448 | Phase Ib/II | Gemcitabine + LY2880070 LY2880070 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | Recruiting | USA | POL | HRV | CAN | 0 |
NCT02637375 | Phase I | Cyclophosphamide + Doxorubicin + Paclitaxel Ganetespib | A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer | Withdrawn | 0 | |
NCT02644369 | Phase II | Pembrolizumab | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) | Active, not recruiting | CAN | 0 |
NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Completed | USA | 0 |
NCT02648477 | Phase II | Letrozole + Pembrolizumab Exemestane + Pembrolizumab Anastrozole + Pembrolizumab Doxorubicin + Pembrolizumab | Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer | Completed | USA | 0 |
NCT02657889 | Phase Ib/II | Niraparib + Pembrolizumab | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO) | Completed | USA | 0 |
NCT02658214 | Phase I | Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | Completed | 2 | |
NCT02660034 | Phase I | Pamiparib + Tislelizumab | The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors | Completed | USA | NZL | GBR | FRA | ESP | AUS | 0 |
NCT02672475 | Phase I | Galunisertib + Paclitaxel | Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer | Completed | USA | 0 |
NCT02676986 | Phase II | Enzalutamide + Exemestane Exemestane Enzalutamide | Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB) | Completed | USA | IRL | GBR | ESP | DEU | 0 |
NCT02689427 | Phase II | Enzalutamide + Paclitaxel | Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer | Completed | USA | 0 |
NCT02698176 | Phase I | Birabresib | A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006) | Terminated | 0 | |
NCT02706392 | Phase I | Cyclophosphamide + Fludarabine + ROR1 CAR-T cells | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Terminated | USA | 0 |
NCT02708680 | Phase Ib/II | Atezolizumab Atezolizumab + Entinostat | Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In | Completed | USA | 1 |
NCT02719691 | Phase I | Alisertib + Sapanisertib | Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer | Completed | USA | 0 |
NCT02720185 | Phase II | Dasatinib | Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR | Terminated | USA | 0 |
NCT02730130 | Phase II | Pembrolizumab | Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients | Completed | USA | 0 |
NCT02734290 | Phase Ib/II | Capecitabine + Pembrolizumab Paclitaxel + Pembrolizumab | Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer | Active, not recruiting | USA | 0 |
NCT02750358 | Phase II | Enzalutamide | Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02752685 | Phase II | Nab-paclitaxel + Pembrolizumab | Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT02755272 | Phase II | Pembrolizumab Carboplatin + Gemcitabine | A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02760797 | Phase I | Emactuzumab + Selicrelumab | A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors | Completed | USA | FRA | BEL | 0 |
NCT02761694 | Phase I | ARQ 751 + Paclitaxel ARQ 751 ARQ 751 + Fulvestrant | ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations | Terminated | USA | 0 |
NCT02762981 | Phase Ib/II | Nab-paclitaxel + Relacorilant | Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors | Completed | USA | 0 |
NCT02768701 | Phase II | Cyclophosphamide + Pembrolizumab | Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer | Completed | USA | 0 |
NCT02783300 | Phase I | GSK3326595 | Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | Completed | USA | NLD | FRA | CAN | 0 |
NCT02784795 | Phase I | Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | DNK | 0 |
NCT02788981 | Phase II | Mifepristone + Nab-paclitaxel Nab-paclitaxel | Abraxane With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02807844 | Phase Ib/II | MCS110 + Spartalizumab | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | ITA | FRA | FIN | ESP | DEU | CHE | BEL | 3 |
NCT02819518 | Phase III | Paclitaxel Pembrolizumab Nab-paclitaxel Carboplatin + Gemcitabine | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) | Completed | 0 | |
NCT02824042 | Phase I | Anetumab ravtansine + Itraconazole Anetumab ravtansine | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | Completed | USA | NLD | FRA | ESP | BEL | AUS | 0 |
NCT02826434 | Phase I | Durvalumab + Poly ICLC + PVX-410 | Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02829723 | Phase Ib/II | BLZ945 BLZ945 + Spartalizumab | Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors | Terminated | USA | ITA | ISR | ESP | CHE | 3 |
NCT02834247 | Phase I | Mivavotinib + Nivolumab | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | Terminated | USA | ITA | GBR | ESP | 0 |
NCT02834403 | Phase Ib/II | Pegfilgrastim Docetaxel + L-NMMA | L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients | Completed | USA | 0 |
NCT02876107 | Phase II | Cyclophosphamide + Doxorubicin Carboplatin + Paclitaxel + Panitumumab Carboplatin + Paclitaxel | Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02876302 | Phase II | Cyclophosphamide + Doxorubicin + Paclitaxel + Ruxolitinib | Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer | Active, not recruiting | USA | 0 |
NCT02880371 | Phase Ib/II | ARRY-382 + Pembrolizumab | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02883062 | Phase II | Carboplatin + Paclitaxel Atezolizumab + Carboplatin + Paclitaxel | Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer | Completed | USA | 0 |
NCT02890069 | Phase I | LCL161 + Spartalizumab Everolimus + Spartalizumab Panobinostat + Spartalizumab | A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | Completed | USA | NLD | GBR | ESP | DEU | 2 |
NCT02898207 | Phase I | Olaparib + Onalespib | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | Completed | USA | 0 |
NCT02900664 | Phase I | Nazartinib + Spartalizumab CJM112 + Spartalizumab Spartalizumab + Trametinib Canakinumab + Spartalizumab Canakinumab | A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib) | Completed | USA | ITA | ISR | FRA | ESP | CAN | BEL | 2 |
NCT02926690 | Phase I | OTS167 | Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT02929576 | Phase III | Paclitaxel Enzalutamide + Paclitaxel Enzalutamide | Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer (ENDEAR) | Withdrawn | USA | 0 |
NCT02936102 | Phase I | FAZ053 FAZ053 + Spartalizumab | A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. | Active, not recruiting | USA | ITA | ISR | FRA | ESP | CAN | 3 |
NCT02938442 | Phase II | Montanide ISA 51 + P10s-PADRE | Vaccination of Triple Negative Breast Cancer Patients | Completed | USA | 0 |
NCT02947165 | Phase I | NIS793 + Spartalizumab NIS793 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | Completed | USA | ITA | DEU | CHE | CAN | AUT | 3 |
NCT02950064 | Phase I | BTP-114 | A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations | Unknown status | USA | 0 |
NCT02952248 | Phase I | Ezabenlimab | A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours | Completed | USA | GBR | CAN | 0 |
NCT02954874 | Phase III | Pembrolizumab | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | Active, not recruiting | USA | CAN | 1 |
NCT02971761 | Phase II | Enobosarm + Pembrolizumab | Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer | Completed | USA | 0 |
NCT02977156 | Phase I | Ipilimumab + JX-594 | Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (ISI-JX) | Completed | FRA | 0 |
NCT02977468 | Phase I | Pembrolizumab | Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT) | Recruiting | USA | 0 |
NCT02978716 | Phase II | Carboplatin + Gemcitabine Carboplatin + Gemcitabine + Trilaciclib | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) | Terminated | USA | SVN | SVK | HRV | BGR | BEL | 2 |
NCT02981303 | Phase II | Pembrolizumab + PGG beta-glucan | Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer | Completed | USA | 0 |
NCT02984683 | Phase II | SAR566658 | Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer | Terminated | NLD | ITA | ESP | CZE | BEL | 0 |
NCT02985658 | Phase I | Cisplatin Veliparib Vinorelbine | Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer | No longer available | USA | 0 |
NCT02996825 | Phase I | Gemcitabine + Mirvetuximab Soravtansine | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | Completed | USA | 0 |
NCT03004183 | Phase II | Pembrolizumab AdV-tk + Valacyclovir | SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC (STOMP) | Completed | USA | 0 |
NCT03012100 | Phase II | Cyclophosphamide + Sargramostim Cyclophosphamide + FR alpha peptide vaccine + Sargramostim | Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03012230 | Phase I | Pembrolizumab + Ruxolitinib | Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer | Completed | USA | 0 |
NCT03012477 | Phase II | Adavosertib + Cisplatin | CISPLATIN + AZD-1775 In Breast Cancer | Completed | USA | 0 |
NCT03018405 | Phase Ib/II | NKR-2 cells | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) | Unknown status | USA | BEL | 0 |
NCT03036488 | Phase III | Cyclophosphamide + Epirubicin Cyclophosphamide + Doxorubicin Pembrolizumab Carboplatin + Paclitaxel | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) | Active, not recruiting | USA | TUR | SWE | POL | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 7 |
NCT03044730 | Phase II | Capecitabine + Pembrolizumab | Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery | Unknown status | USA | 0 |
NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT03090165 | Phase Ib/II | Bicalutamide + Ribociclib | Ribociclib and Bicalutamide in AR+ TNBC | Recruiting | USA | 0 |
NCT03095352 | Phase II | Carboplatin + Pembrolizumab + Trastuzumab Carboplatin Carboplatin + Trastuzumab Carboplatin + Pembrolizumab | Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease | Active, not recruiting | USA | 0 |
NCT03096054 | Phase I | LY3143921 | A CR-UK Phase I Trial of LY3143921 | Active, not recruiting | GBR | 0 |
NCT03098550 | Phase Ib/II | Daratumumab + Nivolumab | A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread | Completed | USA | ITA | FRA | ESP | DEU | CHE | CAN | AUS | 1 |
NCT03102320 | Phase I | Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin | Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) | Completed | USA | NLD | ITA | GBR | FRA | ESP | CHE | CAN | BEL | AUS | 2 |
NCT03106077 | Phase II | Mirvetuximab Soravtansine | Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC) | Completed | USA | 0 |
NCT03106415 | Phase Ib/II | Binimetinib + Pembrolizumab | Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer | Completed | USA | 0 |
NCT03121352 | Phase II | Carboplatin + Nab-paclitaxel + Pembrolizumab | Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer | Completed | USA | 0 |
NCT03125902 | Phase III | Paclitaxel Atezolizumab + Paclitaxel | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131) | Completed | USA | TUR | SVK | ROU | ITA | ISR | HRV | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | ARG | 8 |
NCT03130439 | Phase II | Abemaciclib | Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer | Terminated | USA | 0 |
NCT03150810 | Phase Ib/II | Pamiparib + Temozolomide | Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | GBR | ESP | AUS | 0 |
NCT03167619 | Phase II | Durvalumab + Olaparib Olaparib | Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (DORA) | Completed | USA | 0 |
NCT03184558 | Phase II | Bemcentinib + Pembrolizumab | BGB324 in Combination With Pembrolizumab in Patients With TNBC | Terminated | USA | NOR | GBR | ESP | 0 |
NCT03193853 | Phase II | Cisplatin + Nab-paclitaxel Sapanisertib + Serabelisib | TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer | Completed | USA | 0 |
NCT03197935 | Phase III | Pegfilgrastim Doxorubicin Atezolizumab Filgrastim Nab-paclitaxel Cyclophosphamide | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031) | Completed | USA | POL | ITA | GBR | ESP | DEU | CAN | BRA | BEL | AUS | 3 |
NCT03199040 | Phase I | Durvalumab | Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy | Terminated | USA | 0 |
NCT03205761 | Phase II | Olaparib | Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETABreast) | Completed | ESP | 0 |
NCT03206203 | Phase II | Atezolizumab + Carboplatin Carboplatin | Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03207867 | Phase II | Spartalizumab + Taminadenant | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | Terminated | USA | NLD | ITA | FRA | ESP | DEU | CZE | CHE | BEL | AUT | AUS | ARG | 3 |
NCT03213041 | Phase II | Carboplatin + Pembrolizumab | Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT03221400 | Phase Ib/II | STA-8666 | PEN-866 in Patients With Advanced Solid Malignancies | Unknown status | USA | 0 |
NCT03225547 | Phase II | Mifepristone + Pembrolizumab | Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03243331 | Phase I | Cofetuzumab pelidotin + Gedatolisib | An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer | Completed | USA | 0 |
NCT03256344 | Phase I | Atezolizumab + Talimogene laherparepvec | Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases | Completed | USA | ESP | DEU | CHE | BEL | AUS | 0 |
NCT03281954 | Phase III | Atezolizumab | Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo | Active, not recruiting | USA | CAN | 0 |
NCT03289962 | Phase I | Autogene cevumeran Atezolizumab + Autogene cevumeran | A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Active, not recruiting | USA | SWE | NLD | GBR | ESP | DEU | CAN | BEL | 0 |
NCT03292172 | Phase I | Atezolizumab + TEN-010 | A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | Terminated | USA | GBR | DNK | CAN | AUS | 0 |
NCT03310957 | Phase Ib/II | Ladiratuzumab vedotin + Pembrolizumab | Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer | Active, not recruiting | USA | ESP | DEU | 1 |
NCT03316586 | Phase II | Cabozantinib + Nivolumab | A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer | Completed | USA | 0 |
NCT03316794 | Phase I | SC-005 | A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC) | Terminated | USA | 0 |
NCT03318562 | Phase II | Tomivosertib | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | Terminated | USA | 0 |
NCT03330405 | Phase II | Avelumab + Talazoparib | Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors | Terminated | USA | HUN | GBR | DNK | CAN | BEL | AUS | 2 |
NCT03330847 | Phase II | Adavosertib + Olaparib Olaparib Ceralasertib + Olaparib | To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. | Active, not recruiting | USA | POL | NLD | ITA | IRL | GBR | FRA | ESP | DEU | CZE | CAN | BEL | 3 |
NCT03337724 | Phase II | Ipatasertib + Paclitaxel Paclitaxel | A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130) | Completed | USA | TUR | SVN | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 13 |
NCT03356860 | Phase Ib/II | Cyclophosphamide + Durvalumab + Epirubicin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel | Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. (B-IMMUNE) | Completed | BEL | 0 |
NCT03361800 | Phase I | Entinostat | Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC | Terminated | USA | 0 |
NCT03362060 | Phase I | Pembrolizumab + PVX-410 | PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03363893 | Phase Ib/II | Samuraciclib Fulvestrant + Samuraciclib | Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies | Completed | USA | GBR | 0 |
NCT03366844 | Phase Ib/II | Pembrolizumab | Breast Cancer Study of Preoperative Pembrolizumab + Radiation | Active, not recruiting | USA | 0 |
NCT03371017 | Phase III | Atezolizumab + Capecitabine + Carboplatin + Gemcitabine Capecitabine + Carboplatin + Gemcitabine | A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer (IMpassion132) | Completed | USA | TUR | POL | ITA | HUN | GBR | FRA | FIN | ESP | DEU | BRA | ARG | 16 |
NCT03383679 | Phase II | Darolutamide Capecitabine | Study on Androgen Receptor and Triple Negative Breast Cancer (START) | Completed | FRA | 0 |
NCT03387085 | Phase Ib/II | ETBX-051 Aldoxorubicin ETBX-061 Cisplatin Cyclophosphamide haNK cells GI-4000 Bevacizumab Nogapendekin alfa inbakicept Fluorouracil ETBX-011 Oxaliplatin Capecitabine Leucovorin GI-6301 Nab-paclitaxel Avelumab GI-6207 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | Terminated | USA | 0 |
NCT03414684 | Phase II | Carboplatin + Nivolumab Carboplatin | Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03424005 | Phase Ib/II | Atezolizumab + Bevacizumab + Selicrelumab Atezolizumab + RO6874281 Atezolizumab + Bevacizumab Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Eribulin Capecitabine Atezolizumab Atezolizumab + Bevacizumab + Cobimetinib Atezolizumab + Capecitabine Atezolizumab + Ipatasertib Atezolizumab + Ladiratuzumab vedotin | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC) (Morpheus-TNBC) | Recruiting | USA | ISR | GBR | FRA | ESP | DEU | AUS | 1 |
NCT03435640 | Phase Ib/II | NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 | A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies | Terminated | USA | 0 |
NCT03454451 | Phase I | CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | Completed | USA | AUS | 0 |
NCT03464942 | Phase II | Atezolizumab | Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer (AZTEC) | Completed | AUS | 0 |
NCT03483012 | Phase II | Atezolizumab | Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis | Active, not recruiting | USA | 0 |
NCT03487666 | Phase II | Capecitabine + Nivolumab Capecitabine Nivolumab | OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease | Active, not recruiting | USA | 0 |
NCT03498716 | Phase III | Atezolizumab + Cyclophosphamide + Epirubicin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel Cyclophosphamide + Doxorubicin + Paclitaxel Atezolizumab + Cyclophosphamide + Doxorubicin + Paclitaxel | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030) | Terminated | USA | TUR | ROU | POL | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CHE | BRA | BEL | AUT | AUS | ARG | 11 |
NCT03499899 | Phase II | Carboplatin + Ieramilimab Carboplatin + Ieramilimab + Spartalizumab Ieramilimab + Spartalizumab | A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer | Completed | USA | LBN | ITA | ISR | HUN | FRA | ESP | DEU | CAN | BEL | AUS | ARG | 5 |
NCT03504488 | Phase Ib/II | BA3021 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors | Active, not recruiting | USA | POL | GRC | ESP | 2 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03519178 | Phase II | PF-06873600 | A Study of PF-06873600 in People With Cancer | Active, not recruiting | USA | CAN | BGR | 3 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03542175 | Phase I | Rucaparib | A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy | Active, not recruiting | USA | 0 |
NCT03544125 | Phase I | Durvalumab + Olaparib | Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer | Completed | USA | 0 |
NCT03546686 | Phase II | Ipilimumab + Nivolumab | Peri-Operative Ipilimumab+Nivolumab and Cryoablation in Women With Triple-negative Breast Cancer | Recruiting | USA | 0 |
NCT03554109 | Phase II | Aldoxorubicin + Avelumab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Nogapendekin alfa inbakicept Cyclophosphamide + Doxorubicin + Paclitaxel | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine | Withdrawn | USA | 0 |
NCT03562637 | Phase III | Adagloxad simolenin + OBI-821 | Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC | Recruiting | USA | POL | BRA | AUS | 9 |
NCT03564782 | Phase I | PVSRIPO | Examining Bioactivity of PVSRIPO in Invasive Breast Cancer | Completed | USA | 0 |
NCT03567720 | Phase II | Pembrolizumab + Tavokinogene telseplasmid Nab-paclitaxel + Pembrolizumab + Tavokinogene telseplasmid | Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC | Active, not recruiting | USA | AUS | 0 |
NCT03579472 | Phase I | Bintrafusp alfa + Eribulin | M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer | Terminated | USA | 0 |
NCT03599453 | Phase I | Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod | Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer | Completed | USA | 0 |
NCT03606967 | Phase II | Durvalumab + Nab-paclitaxel + Poly ICLC + Tremelimumab + TSMA-based SLP vaccine Nab-paclitaxel Carboplatin + Gemcitabine Durvalumab + Nab-paclitaxel + Tremelimumab | Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03616886 | Phase Ib/II | Carboplatin + Durvalumab + Oleclumab + Paclitaxel Carboplatin + Durvalumab + Paclitaxel | Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC (SYNERGY) | Active, not recruiting | FRA | BEL | 0 |
NCT03620643 | Phase II | Crizotinib Crizotinib + Fulvestrant | Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (ROLo) | Active, not recruiting | GBR | 0 |
NCT03621982 | Phase I | Camidanlumab tesirine | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Terminated | USA | GBR | BEL | 0 |
NCT03639948 | Phase II | Carboplatin + Docetaxel + Pegfilgrastim + Pembrolizumab | Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer (NeoPACT) | Active, not recruiting | USA | 0 |
NCT03644589 | Phase II | Cisplatin + Pembrolizumab | Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer | Withdrawn | USA | 0 |
NCT03654547 | Phase I | Tinengotinib | Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer | Active, not recruiting | USA | 1 |
NCT03661632 | Phase Ib/II | BMS-986310 + Nivolumab | An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | CAN | BEL | 0 |
NCT03665285 | Phase Ib/II | NC318 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT03667716 | Phase I | COM701 COM701 + Nivolumab | COM701 in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT03674242 | Phase II | Carboplatin + Gemcitabine Carboplatin + Eryaspase + Gemcitabine | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 1st Line Treatment of TNBC (TRYbeCA-2) | Terminated | HUN | ESP | BEL | 0 |
NCT03674567 | Phase Ib/II | FLX475 + Pembrolizumab FLX475 | Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab | Active, not recruiting | USA | AUS | 4 |
NCT03674827 | Phase I | PF-06936308 | A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC | Terminated | USA | 0 |
NCT03681951 | Phase Ib/II | GSK3145095 GSK3145095 + Pembrolizumab | First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors | Terminated | USA | 0 |
NCT03694249 | Phase II | Ifetroban sodium | Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence | Active, not recruiting | USA | 0 |
NCT03700294 | Phase I | ADCT-601 | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors | Terminated | USA | 0 |
NCT03709446 | Phase Ib/II | Leflunomide | Leflunomide in Previously Treated Metastatic Triple Negative Cancers | Recruiting | USA | 0 |
NCT03719326 | Phase I | Eganelisib + Etrumadenant + Pegylated liposomal doxorubicin Etrumadenant + Pegylated liposomal doxorubicin | A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies | Completed | USA | AUS | 0 |
NCT03733119 | Phase II | ONC201 | ONC201 With and Without Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer | Terminated | USA | 0 |
NCT03740893 | Phase II | Olaparib Ceralasertib Durvalumab | PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer (PHOENIX) | Recruiting | GBR | 0 |
NCT03742102 | Phase Ib/II | Durvalumab + Oleclumab + Paclitaxel Durvalumab + Trastuzumab deruxtecan Durvalumab + Paclitaxel Capivasertib + Durvalumab + Paclitaxel | A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA) | Active, not recruiting | USA | POL | GBR | CAN | 2 |
NCT03742349 | Phase I | Canakinumab + Ieramilimab + Spartalizumab Ieramilimab + MCS110 + Spartalizumab Capmatinib + Ieramilimab + Spartalizumab Ieramilimab + Spartalizumab + Taminadenant | Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). | Terminated | USA | NLD | ITA | ISR | ESP | AUS | 3 |
NCT03752398 | Phase I | Izuralimab | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Completed | USA | 0 |
NCT03761914 | Phase Ib/II | Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | Active, not recruiting | USA | 0 |
NCT03775850 | Phase Ib/II | EDP1503 EDP1503 + Pembrolizumab | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | Completed | USA | CAN | 0 |
NCT03797326 | Phase II | Lenvatinib + Pembrolizumab | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | Completed | USA | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | AUS | ARG | 6 |
NCT03800836 | Phase I | Atezolizumab + Ipatasertib + Paclitaxel Atezolizumab + Ipatasertib + Nab-paclitaxel | A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | Completed | USA | GBR | FRA | ESP | AUS | 0 |
NCT03801369 | Phase II | Durvalumab + Olaparib Ceralasertib Olaparib + Selumetinib Capivasertib + Olaparib | Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03802604 | Phase I | Atezolizumab + Talimogene laherparepvec | Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer (PROMETEO) | Active, not recruiting | ESP | 0 |
NCT03812393 | Phase II | Carboplatin + Neratinib + Paclitaxel Neratinib | Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast (FACT-2) | Active, not recruiting | USA | 0 |
NCT03815890 | Phase II | Nivolumab Ipilimumab + Nivolumab | Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO (BELLINI) | Recruiting | NLD | 0 |
NCT03818685 | Phase II | Ipilimumab + Nivolumab Capecitabine | Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease (BreastImmune03) | Active, not recruiting | FRA | 0 |
NCT03821935 | Phase I | ABBV-151 ABBV-151 + Budigalimab | Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | ISR | FRA | ESP | CAN | BEL | AUS | 4 |
NCT03829501 | Phase Ib/II | Atezolizumab + KY1044 KY1044 | Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer | Terminated | USA | POL | ITA | HUN | GBR | 1 |
NCT03838367 | Phase Ib/II | Carboplatin + Leronlimab | Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC | Unknown status | USA | 0 |
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Completed | USA | 0 |
NCT03853707 | Phase Ib/II | Carboplatin + Ipatasertib + Paclitaxel Carboplatin + Ipatasertib Atezolizumab + Capecitabine + Ipatasertib | Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer | Completed | USA | 0 |
NCT03861403 | Phase Ib/II | Avelumab + Cyclophosphamide + TRX518 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | Terminated | USA | 0 |
NCT03872388 | Phase II | Atorvastatin + Capecitabine Capecitabine | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy | Terminated | USA | 0 |
NCT03872505 | Phase II | Carboplatin + Durvalumab + Paclitaxel | Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer (PANDoRA) | Withdrawn | USA | 0 |
NCT03875313 | Phase Ib/II | Talazoparib + Telaglenastat | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | Terminated | USA | 0 |
NCT03891953 | Phase I | DKY709 DKY709 + Spartalizumab | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | Active, not recruiting | USA | ESP | DEU | 3 |
NCT03893955 | Phase I | ABBV-368 + ABBV-927 + Nab-paclitaxel ABBV-368 + ABBV-927 ABBV-368 + ABBV-927 + Budigalimab ABBV-927 + Budigalimab + Carboplatin ABBV-927 + Carboplatin ABBV-368 + ABBV-927 + Carboplatin | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ISR | FRA | ESP | AUS | 1 |
NCT03901469 | Phase II | Talazoparib + ZEN-3694 | A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC) | Terminated | USA | ESP | BEL | 1 |
NCT03911453 | Phase I | Rucaparib | Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors | Completed | USA | 0 |
NCT03911973 | Phase Ib/II | Gedatolisib + Talazoparib | Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers | Active, not recruiting | USA | 0 |
NCT03915678 | Phase II | Atezolizumab + BDB001 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (AGADIR) | Recruiting | FRA | 0 |
NCT03917381 | Phase Ib/II | GEN1046 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | Active, not recruiting | USA | TUR | POL | ITA | ISR | HUN | ESP | CZE | 2 |
NCT03941730 | Phase II | Estradiol | Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT03945721 | Phase I | Niraparib | A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients (UNITY) | Active, not recruiting | USA | 0 |
NCT03950570 | Phase I | ORIN1001 + Paclitaxel ORIN1001 | ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT03952325 | Phase II | Pembrolizumab + Tesetaxel Nivolumab + Tesetaxel Tesetaxel Atezolizumab + Tesetaxel | Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Patients With HER2 Negative MBC (CONTESSA TRIO) | Terminated | USA | 2 |
NCT03961698 | Phase II | Atezolizumab + Bevacizumab + Eganelisib Atezolizumab + Eganelisib + Nab-paclitaxel | Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3) (MARIO-3) | Active, not recruiting | USA | 0 |
NCT03971409 | Phase II | Avelumab + PF-04518600 Avelumab + Utomilumab Avelumab + Binimetinib | Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Negative Breast Cancer (InCITe) | Recruiting | USA | 0 |
NCT03977467 | Phase II | Atezolizumab + Carboplatin Atezolizumab + Tiragolumab Atezolizumab + Cisplatin Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin | Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | Completed | USA | 0 |
NCT03979508 | Phase II | Abemaciclib | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03990233 | Phase I | Effi-DEM Effi-DEM + Ezabenlimab | A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | Active, not recruiting | FRA | BEL | 0 |
NCT03990896 | Phase II | Talazoparib | Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial | Recruiting | USA | 0 |
NCT03992131 | Phase Ib/II | Lucitanib + Rucaparib Rucaparib + Sacituzumab govitecan-hziy | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) | Terminated | USA | 0 |
NCT03997123 | Phase III | Paclitaxel Capivasertib + Paclitaxel | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC (CapItello290) | Active, not recruiting | USA | TUR | SWE | SVK | POL | HUN | GRC | GBR | FRA | ESP | CZE | CAN | BRA | ARG | 16 |
NCT03997968 | Phase Ib/II | CYT01B | A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04024436 | Phase II | Fulvestrant + Futibatinib Futibatinib | A Study of TAS-120 in Patients With Metastatic Breast Cancer | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | 1 |
NCT04024800 | Phase II | AE37 + Pembrolizumab | Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NSABP FB-14) | Unknown status | USA | 0 |
NCT04032080 | Phase II | Prexasertib LY3023414 | Treatment With Oral LY3023414 To Inhibit Homologous Recombination Followed By Prexasertib (ExIST) | Completed | USA | 0 |
NCT04039230 | Phase Ib/II | Sacituzumab govitecan-hziy + Talazoparib | Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. | Recruiting | USA | 0 |
NCT04041128 | Phase I | Olaparib | PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer | Completed | USA | 0 |
NCT04052555 | Phase I | Berzosertib | Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT04060342 | Phase Ib/II | GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | Terminated | USA | GBR | 0 |
NCT04081389 | Phase I | Celecoxib + Cyclophosphamide + Doxorubicin + Interferon alpha-2b + Paclitaxel + Rintatolimod | Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer | Completed | USA | 0 |
NCT04095689 | Phase II | Cyclophosphamide + Docetaxel + Doxorubicin + IL-12 gene + L-NMMA + Pembrolizumab | TAC Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy and L-NMMA in Triple Negative Breast Cancer | Suspended | USA | 0 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04102618 | Phase I | Atezolizumab + Pelareorep Atezolizumab + Pelareorep + Trastuzumab Letrozole + Pelareorep Atezolizumab + Letrozole + Pelareorep | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1) | Terminated | ESP | 0 |
NCT04111510 | Phase II | LN-145 | Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer | Completed | USA | 0 |
NCT04115306 | Phase I | PMD-026 | Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT04123704 | Phase II | Sitravatinib | Sitravatinib in Metastatic Breast Cancer | Terminated | USA | 0 |
NCT04148911 | Phase III | Atezolizumab + Nab-paclitaxel | A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer (EL1SSAR) | Active, not recruiting | SVN | ROU | POL | ITA | HUN | FRA | ESP | CZE | ARG | 4 |
NCT04152499 | Phase Ib/II | SKB264 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) | Recruiting | USA | TUR | CAN | 2 |
NCT04159818 | Phase II | Nivolumab Doxorubicin + Nivolumab Cisplatin + Nivolumab | Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients (TONIC-2) | Recruiting | NLD | 0 |
NCT04176848 | Phase II | CFI-400945 + Durvalumab | CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer | Active, not recruiting | CAN | 0 |
NCT04177108 | Phase III | Ipatasertib + Paclitaxel Atezolizumab + Paclitaxel Atezolizumab + Ipatasertib + Paclitaxel Paclitaxel | A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer. | Completed | USA | TUR | ROU | POL | NZL | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DNK | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 15 |
NCT04185311 | Phase I | Ipilimumab + Nivolumab + Talimogene laherparepvec | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted | Terminated | USA | 0 |
NCT04191135 | Phase II | Carboplatin + Gemcitabine + Pembrolizumab Carboplatin + Gemcitabine + Olaparib + Pembrolizumab | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) | Active, not recruiting | USA | POL | IRL | HUN | GBR | FRA | ESP | DEU | CAN | 6 |
NCT04216472 | Phase II | Alpelisib + Nab-paclitaxel | Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations | Active, not recruiting | USA | 0 |
NCT04225117 | Phase II | Enfortumab vedotin-ejfv | A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | Active, not recruiting | USA | CAN | 1 |
NCT04230109 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab Govitecan In TNBC (NeoSTAR) | Recruiting | USA | 0 |
NCT04243616 | Phase II | Carboplatin + Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel | Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer | Recruiting | USA | 0 |
NCT04249167 | Phase I | Atezolizumab + Nab-paclitaxel | Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer | Withdrawn | 0 | |
NCT04251533 | Phase III | Alpelisib + Nab-paclitaxel Nab-paclitaxel | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (EPIK-B3) | Active, not recruiting | USA | TUR | SVN | SVK | POL | NOR | ITA | ISR | HUN | HRV | GBR | FRA | ESP | DEU | CHE | BRA | BGR | AUT | AUS | ARG | 10 |
NCT04260802 | Phase Ib/II | OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Recruiting | CAN | 0 |
NCT04265872 | Phase I | Bortezomib + Cisplatin + Pembrolizumab | Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC | Recruiting | USA | 0 |
NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Completed | AUS | 1 |
NCT04282044 | Phase I | CRX100 | Study of CRX100 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04300556 | Phase Ib/II | MORAb-202 | A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Recruiting | USA | GBR | FRA | ESP | 0 |
NCT04315233 | Phase I | Belinostat + Ribociclib | Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics (CHARGE) | Recruiting | USA | 0 |
NCT04331067 | Phase Ib/II | Cabiralizumab + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Paclitaxel | Cabiralizumab in Combination With Nivolumab and Neoadjuvant Chemotherapy in Patients With Localized Triple-negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT04332653 | Phase Ib/II | NT-I7 + Pembrolizumab | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04333706 | Phase Ib/II | Capecitabine Capecitabine + Sarilumab | A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) (EMPOWER) | Recruiting | USA | 0 |
NCT04335669 | Phase III | Cyclophosphamide + Epirubicin + Pembrolizumab Pembrolizumab Carboplatin + Paclitaxel Capecitabine + Cyclophosphamide + Epirubicin | NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC | Recruiting | SWE | DNK | 0 |
NCT04338685 | Phase I | RO7119929 + Tocilizumab | A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases | Completed | USA | ESP | DNK | 3 |
NCT04344795 | Phase I | TPST-1495 Pembrolizumab + TPST-1495 | Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors | Active, not recruiting | USA | 0 |
NCT04345913 | Phase Ib/II | Eribulin Copanlisib + Eribulin | Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT04348747 | Phase II | Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Rintatolimod | Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer | Recruiting | USA | 0 |
NCT04360941 | Phase I | Avelumab + Palbociclib | PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer (PAveMenT) | Recruiting | GBR | 0 |
NCT04373031 | Phase II | Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Cyclophosphamide + Doxorubicin + IRX-2 + Paclitaxel + Pembrolizumab | Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT04408118 | Phase II | Atezolizumab + Bevacizumab + Paclitaxel | First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin) in mTNBC (ATRACTIB) | Completed | ITA | GBR | FRA | ESP | DEU | 0 |
NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 0 |
NCT04424641 | Phase Ib/II | GEN1044 | A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors | Terminated | USA | ISR | ESP | DNK | 0 |
NCT04427293 | Phase I | Lenvatinib + Pembrolizumab | Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) | Recruiting | USA | 0 |
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT04432857 | Phase I | E7046 + Pembrolizumab | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | Active, not recruiting | USA | FRA | 0 |
NCT04434040 | Phase II | Atezolizumab + Ipatasertib | Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC | Active, not recruiting | USA | 0 |
NCT04434482 | Phase I | Senaparib + Temozolomide | IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer | Completed | USA | AUS | 3 |
NCT04434560 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Immunotherapy in Brain Metastases | Terminated | USA | 0 |
NCT04441099 | Phase Ib/II | NBE-002 | NBE-002 in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04443348 | Phase II | Pembrolizumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab | Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) | Recruiting | USA | 0 |
NCT04445844 | Phase II | Pelareorep + Retifanlimab | INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study | Recruiting | USA | 0 |
NCT04454528 | Phase Ib/II | Pembrolizumab | BreastVax: Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer | Recruiting | USA | 0 |
NCT04461600 | Phase II | BMS-906024 | A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer (TENACITY) | Terminated | USA | ISR | GBR | ESP | BEL | 0 |
NCT04464174 | Phase II | Eribulin + Ipatasertib Capecitabine + Ipatasertib Carboplatin + Gemcitabine + Ipatasertib | Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer (PATHFINDER) | Completed | ESP | 1 |
NCT04468061 | Phase II | Sacituzumab govitecan-hziy Pembrolizumab + Sacituzumab govitecan-hziy | Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | Recruiting | USA | 0 |
NCT04489940 | Phase II | Bintrafusp alfa | Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer | Terminated | USA | ITA | FRA | ESP | BEL | 1 |
NCT04491942 | Phase I | Cisplatin + Elimusertib Cisplatin + Elimusertib + Gemcitabine | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | Active, not recruiting | USA | CAN | 0 |
NCT04494958 | Phase Ib/II | Binimetinib + Palbociclib | Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer (PALBOBIN) | Completed | ESP | 0 |
NCT04504669 | Phase I | AZD8701 + Durvalumab AZD8701 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | Completed | USA | FRA | ESP | CAN | 0 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Active, not recruiting | USA | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04521621 | Phase Ib/II | Coxsackievirus A21 + Pembrolizumab | A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | Terminated | USA | POL | NOR | ITA | ISR | HUN | FRA | ESP | DEU | CAN | 4 |
NCT04553133 | Phase II | PF-07104091 Letrozole + Palbociclib + PF-07104091 Palbociclib + PF-07104091 | PF-07104091 as a Single Agent and in Combination Therapy | Active, not recruiting | USA | BGR | ARG | 3 |
NCT04561362 | Phase Ib/II | BT8009 BT8009 + Pembrolizumab | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT04574583 | Phase Ib/II | Bintrafusp alfa + FPV-CV301 + MVA-BN-CV301 + SX-682 | Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) | Completed | USA | 0 |
NCT04577963 | Phase Ib/II | Fruquintinib + Tislelizumab | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT04580485 | Phase I | INCB106385 + Retifanlimab INCB106385 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | Completed | USA | ITA | GBR | FRA | ESP | BEL | 0 |
NCT04584112 | Phase I | Atezolizumab + Cyclophosphamide + Doxorubicin + Pegfilgrastim + Tiragolumab Atezolizumab + Cyclophosphamide + Doxorubicin + Sargramostim + Tiragolumab Atezolizumab + Nab-paclitaxel + Tiragolumab Atezolizumab + Cyclophosphamide + Doxorubicin + Filgrastim + Tiragolumab | A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer | Completed | USA | ESP | DEU | BRA | AUS | 3 |
NCT04592653 | Phase Ib/II | ALKS 4230 ALKS 4230 + Pembrolizumab | Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) | Active, not recruiting | USA | ESP | 0 |
NCT04596150 | Phase II | CX-2009 CX-072 + CX-2009 | Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer | Completed | USA | ESP | 1 |
NCT04622774 | Phase I | IMGC936 | First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors | Completed | USA | ITA | ESP | 0 |
NCT04639245 | Phase Ib/II | MAGE-A1-specific TCR cells + unspecified PD-1 antibody Cyclophosphamide + Fludarabine Atezolizumab + MAGE-A1-specific TCR cells MAGE-A1-specific TCR cells | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04683679 | Phase II | Olaparib + Pembrolizumab Pembrolizumab | A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer | Recruiting | USA | 0 |
NCT04690855 | Phase II | Atezolizumab + Talazoparib | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer (TARA) | Terminated | USA | 0 |
NCT04691375 | Phase I | Pembrolizumab + PY314 PY314 | A Study of PY314 in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04699630 | Phase II | Patritumab deruxtecan | A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT04706962 | Phase I | TH1902 | TH1902 in Patients With Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04711824 | Phase Ib/II | Nab-paclitaxel Carboplatin + Gemcitabine Cisplatin Durvalumab + Olaparib Paclitaxel Capecitabine Gemcitabine Carboplatin Eribulin | Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases (SOLARA) | Recruiting | USA | 0 |
NCT04725331 | Phase Ib/II | BT-001 BT-001 + Pembrolizumab | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | Recruiting | FRA | BEL | 0 |
NCT04726332 | Phase I | Abiraterone + Prednisone + XL102 Fulvestrant + XL102 XL102 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | Terminated | USA | 0 |
NCT04739670 | Phase II | Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine | Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer (BELLA) | Recruiting | AUS | 0 |
NCT04762901 | Phase I | Cyclophosphamide + Doxorubicin + Niraparib + Pegfilgrastim Cyclophosphamide + Doxorubicin + Niraparib Niraparib + Paclitaxel Carboplatin + Niraparib + Paclitaxel | LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer | Withdrawn | 0 | |
NCT04770272 | Phase II | Atezolizumab + Carboplatin + Paclitaxel Atezolizumab + Cyclophosphamide + Epirubicin Atezolizumab | Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono) | Completed | DEU | 0 |
NCT04787042 | Phase Ib/II | Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Active, not recruiting | USA | 0 |
NCT04789668 | Phase Ib/II | Bintrafusp alfa + Pimasertib | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | Completed | USA | 0 |
NCT04799249 | Phase III | Carboplatin + Gemcitabine Carboplatin + Gemcitabine + Trilaciclib | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) (PRESERVE 2) | Completed | USA | POL | FRA | ESP | BGR | AUS | 5 |
NCT04807192 | Phase II | Vidutolimod | CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC) | Recruiting | CHE | 0 |
NCT04808362 | Phase Ib/II | OMO-103 | Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (MYCure) | Terminated | ESP | 0 |
NCT04837209 | Phase II | Dostarlimab-gxly + Niraparib | Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (NADiR) | Recruiting | USA | 0 |
NCT04837677 | Phase I | PRT1419 | A Study of PRT1419 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04849364 | Phase II | Capecitabine + Inavolisib Atezolizumab + Capecitabine Capecitabine + Talazoparib Capecitabine Atezolizumab + Capecitabine + Talazoparib | Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE) | Active, not recruiting | USA | 0 |
NCT04878484 | Phase I | TCRT-ESO-A2 | Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors | Withdrawn | 0 | |
NCT04879849 | Phase I | Pembrolizumab + TAK-676 | A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers | Completed | USA | 0 |
NCT04915755 | Phase III | Niraparib | Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST) | Active, not recruiting | USA | ROU | POL | NOR | NLD | ITA | ISR | IRL | HUN | GBR | FRA | FIN | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 6 |
NCT04916002 | Phase II | Cemiplimab + Vidutolimod | CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer | Terminated | USA | AUS | 0 |
NCT04925284 | Phase I | XB002 Nivolumab + XB002 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS | 1 |
NCT04927884 | Phase Ib/II | Cyclophosphamide + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells + Sacituzumab govitecan-hziy | A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies | Terminated | USA | 0 |
NCT04947189 | Phase Ib/II | Dexamethasone + Docetaxel + Seviteronel | Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer (4CAST) | Recruiting | AUS | 0 |
NCT04958239 | Phase I | BI 765179 + Ezabenlimab BI 765179 | A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer | Recruiting | USA | NLD | ITA | ISR | FRA | ESP | DEU | CZE | BRA | BEL | AUS | 4 |
NCT04958785 | Phase II | Hu5F9-G4 + Nab-paclitaxel Hu5F9-G4 + Sacituzumab govitecan-hziy Nab-paclitaxel Paclitaxel Hu5F9-G4 + Paclitaxel | Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC) | Terminated | USA | GBR | AUS | 3 |
NCT04972981 | Phase I | ADCT-901 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors | Active, not recruiting | USA | GBR | ESP | 0 |
NCT04986852 | Phase II | Pembrolizumab + Tanibirumab | Olinvacimab With Pembrolizumab in Patients With mTNBC | Recruiting | AUS | 0 |
NCT04992013 | Phase II | Niraparib | Niraparib in Tumors Metastatic to the CNS | Recruiting | USA | 0 |
NCT05001282 | Phase Ib/II | ELU001 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) | Terminated | USA | 0 |
NCT05001347 | Phase II | Uliledlimab | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ) in Patients With Ovarian Cancer and Selected Solid Tumors | Completed | USA | 0 |
NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | ISR | 0 |
NCT05007106 | Phase II | MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | FRA | ESP | DEU | CAN | 5 |
NCT05020860 | Phase II | Cyclophosphamide + Doxorubicin + Paclitaxel Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer (RESPONSE) | Recruiting | USA | 0 |
NCT05043714 | Phase I | NG-641 + Nivolumab | Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA) | Active, not recruiting | USA | GBR | 0 |
NCT05052255 | Phase Ib/II | RVU120 | RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid Tumors | Active, not recruiting | POL | ESP | 0 |
NCT05057013 | Phase Ib/II | HMBD-001 | HMBD-001 in Advanced HER3 Positive Solid Tumours | Recruiting | GBR | 0 |
NCT05064280 | Phase II | Lenvatinib Pembrolizumab | Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | Recruiting | USA | 0 |
NCT05067530 | Phase II | Paclitaxel Palbociclib Carboplatin Carboplatin + Paclitaxel Paclitaxel + Palbociclib | Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study (CAREGIVER) | Not yet recruiting | POL | 0 |
NCT05067972 | Phase I | PF-07260437 | A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (C4431001) | Terminated | USA | 1 |
NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Terminated | USA | 0 |
NCT05070247 | Phase I | TAK-500 Pembrolizumab + TAK-500 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05076760 | Phase I | MEM-288 | Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | 0 |
NCT05082259 | Phase I | ASTX-660 + Pembrolizumab | ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab (ASTEROID) | Recruiting | GBR | 0 |
NCT05082610 | Phase I | HMBD-002 HMBD-002 + Pembrolizumab | A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab | Recruiting | USA | 0 |
NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | CAN | AUS | 1 |
NCT05093387 | Phase I | Carboplatin + Pembrolizumab + SGT-53 | SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer | Withdrawn | USA | 0 |
NCT05094804 | Phase Ib/II | Nivolumab + OR2805 OR2805 + Pembrolizumab OR2805 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor | Recruiting | USA | 0 |
NCT05095207 | Phase Ib/II | Abemaciclib + Bicalutamide | Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT05101070 | Phase Ib/II | Pembrolizumab + S-531011 Pembrolizumab S-531011 | S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001) | Recruiting | USA | 1 |
NCT05107674 | Phase I | NX-1607 | A Study of NX-1607 in Adults With Advanced Malignancies | Recruiting | USA | GBR | 0 |
NCT05111561 | Phase I | Binimetinib + ZEN-3694 | Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer | Suspended | USA | 0 |
NCT05112536 | Phase II | Cyclophosphamide + Doxorubicin + Pembrolizumab + Trilaciclib Carboplatin + Paclitaxel + Trilaciclib Trilaciclib | Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer | Completed | USA | 0 |
NCT05113966 | Phase II | Sacituzumab govitecan-hziy + Trilaciclib | Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer | Completed | USA | 0 |
NCT05123482 | Phase Ib/II | AZD8205 | First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies | Recruiting | USA | POL | NLD | ITA | HUN | GBR | ESP | CAN | BEL | AUS | 5 |
NCT05128734 | Phase II | Olaparib + Temozolomide Temozolomide | Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) | Not yet recruiting | CAN | 0 |
NCT05142592 | Phase I | IPG7236 | IPG7236 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05143229 | Phase I | Alpelisib + Sacituzumab govitecan-hziy | Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer (ASSET) | Recruiting | USA | 0 |
NCT05144698 | Phase II | RAPA-201 | RAPA-201 Therapy of Solid Tumors | Recruiting | USA | 0 |
NCT05177796 | Phase II | Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Panitumumab + Pembrolizumab | Anti-EGFR and Immunotherapy for TN-IBC (TN-IBC) | Withdrawn | USA | 0 |
NCT05180006 | Phase II | Atezolizumab Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Ipatasertib Atezolizumab + Bevacizumab | Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program) | Recruiting | FRA | 0 |
NCT05181462 | Phase Ib/II | Carboplatin + Gemcitabine Carboplatin + Gemcitabine + Nidanilimab | Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. (TRIFOUR) | Recruiting | ESP | 0 |
NCT05194072 | Phase I | SGN-B7H4V | A Study of SGN-B7H4V in Advanced Solid Tumors | Recruiting | USA | ITA | GBR | ESP | DEU | CAN | 0 |
NCT05198843 | Phase Ib/II | Dasatinib + Icosapent Ethyl | Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body | Terminated | USA | 0 |
NCT05203445 | Phase II | Olaparib + Pembrolizumab | A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer | Recruiting | USA | 0 |
NCT05215106 | Phase II | Durvalumab | Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva) (POP-DURVA) | Recruiting | FRA | 0 |
NCT05233696 | Phase II | Nab-paclitaxel + Pembrolizumab Paclitaxel + Pembrolizumab | Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC | Withdrawn | USA | 0 |
NCT05252390 | Phase Ib/II | NUV-868 NUV-868 + Olaparib Enzalutamide + NUV-868 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT05255666 | Phase II | Liposomal irinotecan + Pembrolizumab | Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM) | Withdrawn | 0 | |
NCT05263180 | Phase I | EMB-09 | A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | Recruiting | AUS | 1 |
NCT05269381 | Phase I | Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) | Recruiting | USA | 0 |
NCT05272709 | Phase Ib/II | TT-702 | TT-702 in Patients With Advanced Solid Tumours. (CURATE) | Recruiting | GBR | 0 |
NCT05274451 | Phase I | LYL797 | A Study to Investigate LYL797 in Adults with Solid Tumors | Active, not recruiting | USA | 0 |
NCT05279300 | Phase I | CS5001 | A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | Recruiting | USA | AUS | 1 |
NCT05298592 | Phase I | BMS-986406 + Nivolumab BMS-986406 | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | Completed | USA | ESP | BEL | ARG | 2 |
NCT05306444 | Phase I | HBM7008 | CLN-418 Study on Subjects With Advanced Solid Tumors | Completed | USA | AUS | 0 |
NCT05317078 | Phase I | AMG 794 | A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications | Terminated | USA | CHE | AUS | 0 |
NCT05318469 | Phase II | Ivermectin + Pembrolizumab | Ivermectin and Pembrolizumab for the Treatment of Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT05325866 | Phase I | Bemarituzumab | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301) | Recruiting | USA | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 4 |
NCT05329532 | Phase Ib/II | Modi-1 Modi-1 + Pembrolizumab | Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer (ModiFY) | Recruiting | GBR | 0 |
NCT05332561 | Phase II | Olaparib Ipatasertib Sacituzumab govitecan-hziy Inavolisib Pertuzumab/trastuzumab/hyaluronidase-zzxf Atezolizumab | Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) | Recruiting | DEU | 0 |
NCT05340413 | Phase II | Olaparib | Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (RADIOLA) | Recruiting | ESP | 0 |
NCT05358379 | Phase Ib/II | CYC140 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Recruiting | USA | ESP | 1 |
NCT05358639 | Phase I | Navitoclax + Olaparib | Combination of Olaparib and Navitoclax in Women With HGSC and TNBC | Recruiting | CAN | 0 |
NCT05368506 | Phase I | ZN-c3 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer | Withdrawn | 0 | |
NCT05374512 | Phase III | Eribulin Nab-paclitaxel Paclitaxel Datopotamab deruxtecan Carboplatin Capecitabine | A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy | Active, not recruiting | USA | TUR | POL | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | ARG | 10 |
NCT05382286 | Phase III | Pembrolizumab + Sacituzumab govitecan-hziy Carboplatin + Gemcitabine + Pembrolizumab Paclitaxel + Pembrolizumab Nab-paclitaxel + Pembrolizumab | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
NCT05382299 | Phase III | Nab-paclitaxel Carboplatin + Gemcitabine Sacituzumab govitecan-hziy Paclitaxel | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer (ASCENT-03) | Recruiting | USA | TUR | SVK | ROU | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 11 |
NCT05383170 | Phase Ib/II | Cypep-1 + Pembrolizumab | A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (Catalyst) | Completed | USA | NLD | ITA | FRA | ESP | 0 |
NCT05383196 | Phase Ib/II | Onvansertib + Paclitaxel | Phase 1b/2 Study of Onvansertib + Paclitaxel in Triple-Negative Breast Cancer (TNBC) | Recruiting | USA | 0 |
NCT05388435 | Phase Ib/II | SKL27969 | Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients | Terminated | USA | 0 |
NCT05403554 | Phase I | NI-1801 | A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers | Recruiting | ITA | FRA | 0 |
NCT05422794 | Phase I | Nab-paclitaxel + Pembrolizumab + ZEN-3694 | Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer | Suspended | USA | 0 |
NCT05438329 | Phase Ib/II | DB-1305 | First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors | Recruiting | USA | 2 |
NCT05451784 | Phase Ib/II | NUMARZU-001 | Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS (TILS001) | Recruiting | ESP | 0 |
NCT05451849 | Phase Ib/II | Cyclophosphamide + Fludarabine TC-510 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Active, not recruiting | USA | 0 |
NCT05453825 | Phase II | Irinotecan + Navicixizumab Navicixizumab Navicixizumab + Paclitaxel | A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05455658 | Phase II | Sargramostim + STEMVAC | STEMVAC in Patients With Early Stage Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT05483491 | Phase I | Aldesleukin + KK-LC-1 TCR-T cells | KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer | Recruiting | USA | 0 |
NCT05491226 | Phase II | Axatilimab + Pembrolizumab | Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation | Recruiting | USA | 0 |
NCT05492682 | Phase I | Cyclophosphamide + Pembrolizumab + PeptiCRAd-1 | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | Recruiting | DEU | 0 |
NCT05498597 | Phase I | AMT-151 | AMT-151 in Patients With Selected Advanced Solid Tumours | Recruiting | AUS | 1 |
NCT05520723 | Phase II | Loperamide + Sacituzumab govitecan-hziy + Sargramostim | Preventive stRategy for IMMU132-relatED AEs in TNBC (PRIMED) | Active, not recruiting | ESP | 0 |
NCT05533697 | Phase Ib/II | mRNA-4359 + Pembrolizumab mRNA-4359 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | ESP | AUS | 0 |
NCT05537740 | Phase I | BAY 3375968 + Pembrolizumab BAY 3375968 | A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CAN | BEL | 2 |
NCT05539365 | Phase Ib/II | Pembrolizumab | Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer | Not yet recruiting | USA | 0 |
NCT05544929 | Phase I | KFA115 KFA115 + Pembrolizumab | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | Recruiting | USA | ITA | ESP | DEU | CAN | 4 |
NCT05552001 | Phase III | Sacituzumab govitecan-hziy | Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer (ISIdE) | Recruiting | FRA | 0 |
NCT05565417 | Phase Ib/II | IMT-009 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | Recruiting | USA | 0 |
NCT05570253 | Phase II | Eribulin + SDX-7320 Eribulin | A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer | Recruiting | USA | 0 |
NCT05579366 | Phase Ib/II | PRO1184 | PRO1184 for Advanced Solid Tumors (PRO1184-001) | Recruiting | USA | 1 |
NCT05582538 | Phase II | Ceralasertib + Durvalumab + Nab-paclitaxel | Ceralasertib Followed by Durvalumab and Nab-paclitaxel Combination in mTNBC Patients (ATRiBRAVE) | Recruiting | ITA | 0 |
NCT05585034 | Phase I | Pembrolizumab + XmAb808 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb808 in Combination With Pembrolizumab in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05592626 | Phase Ib/II | STAR0602 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) | Recruiting | USA | FRA | ESP | CAN | 0 |
NCT05605509 | Phase II | Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306 | RP-6306 in Patients With Advanced Cancer | Recruiting | CAN | 0 |
NCT05607498 | Phase I | EMB-07 | First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors | Recruiting | AUS | 1 |
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Active, not recruiting | ESP | BEL | 0 |
NCT05620914 | Phase I | Patritumab deruxtecan | A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) | Not yet recruiting | USA | 0 |
NCT05623488 | Phase I | HuCART-meso cells | CAR T Cells in Mesothelin-Expressing Breast Cancer | Recruiting | USA | 0 |
NCT05625412 | Phase I | CC-90001 + Nivolumab Capecitabine + CC-90001 CC-90001 CC-90001 + Docetaxel | A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | CAN | AUS | ARG | 2 |
NCT05627960 | Phase I | AG01 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT05629585 | Phase III | Datopotamab deruxtecan Capecitabine + Pembrolizumab Datopotamab deruxtecan + Durvalumab | A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy | Recruiting | USA | SWE | ITA | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | 5 |
NCT05633654 | Phase III | Pembrolizumab + Sacituzumab govitecan-hziy Capecitabine + Pembrolizumab Pembrolizumab | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63) | Recruiting | USA | 0 |
NCT05642949 | Phase Ib/II | MHB036C | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05645380 | Phase II | Cyclophosphamide + Doxorubicin + Pembrolizumab Carboplatin + Docetaxel + Pembrolizumab | Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC (NeoTRACT) | Recruiting | USA | 0 |
NCT05660083 | Phase II | Alpelisib + L-NMMA + Nab-paclitaxel | Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) | Recruiting | USA | 0 |
NCT05673200 | Phase I | Decitabine and Cedazuridine + Paclitaxel + Pembrolizumab | Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer | Suspended | USA | 0 |
NCT05684965 | Phase I | XTX301 | XTX301 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05700721 | Phase II | Dostarlimab-gxly + Niraparib | Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) | Recruiting | USA | 0 |
NCT05704985 | Phase I | DK210 DK210 + Nivolumab Paclitaxel DK210 + Pembrolizumab Oxaliplatin Capecitabine Fluorouracil Carboplatin | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | Recruiting | USA | 0 |
NCT05714553 | Phase Ib/II | Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT05719558 | Phase I | ASP1002 | A Study of ASP1002 in Adults for Treatment of Solid Tumors | Recruiting | USA | 0 |
NCT05741164 | Phase II | Pembrolizumab + Propranolol | Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer | Not yet recruiting | USA | 0 |
NCT05746897 | Phase I | NM1F + Pembrolizumab NM1F | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05756166 | Phase Ib/II | Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod | Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT05812807 | Phase III | Pembrolizumab | Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Recruiting | USA | CAN | 1 |
NCT05826600 | Phase I | OMX-0407 | A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically | Recruiting | ESP | BEL | 0 |
NCT05836324 | Phase I | INCA33890 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | CHE | 0 |
NCT05846789 | Phase II | Carboplatin + Tocilizumab Carboplatin | Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers | Recruiting | USA | 0 |
NCT05848739 | Phase I | ST316 | A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05852691 | Phase II | Nab-paclitaxel + RO7247669 Nab-paclitaxel + Pembrolizumab | A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer | Recruiting | USA | POL | NLD | ITA | ISR | HUN | ESP | DNK | DEU | CZE | BRA | AUS | ARG | 6 |
NCT05865990 | Phase II | Patritumab deruxtecan | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease (TUXEDO-3) | Active, not recruiting | ESP | AUT | 0 |
NCT05866432 | Phase II | Datopotamab deruxtecan | Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases (TUXEDO-2) | Recruiting | AUT | 0 |
NCT05886868 | Phase I | BL0020 | Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors | Recruiting | AUS | 1 |
NCT05888831 | Phase Ib/II | BMS-986449 + Nivolumab BMS-986449 | A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors | Recruiting | USA | NLD | ITA | FRA | ESP | BEL | 0 |
NCT05891171 | Phase I | AB598 + Carboplatin + Pemetrexed Disodium + Zimberelimab AB598 AB598 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25) | Recruiting | USA | AUS | 0 |
NCT05902988 | Phase Ib/II | VLS-1488 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Recruiting | USA | 0 |
NCT05904496 | Phase I | BGB-30813 BGB-30813 + Tislelizumab | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ESP | AUS | 0 |
NCT05929768 | Phase III | Cyclophosphamide + Doxorubicin + Pembrolizumab Carboplatin + Docetaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab | Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | Recruiting | USA | 1 |
NCT05947474 | Phase I | ORB-011 | ORB-011 In Patients With Advanced Solid Tumors (ORB) | Recruiting | USA | 0 |
NCT05958199 | Phase I | NPX267 | Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 | Recruiting | USA | 0 |
NCT05969041 | Phase I | MT-302 | Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony) | Recruiting | AUS | 0 |
NCT05989828 | Phase I | Cyclophosphamide + Fludarabine Autologous anti-HLA-A2/NY-ESO-1 TCR T cells | A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer | Not yet recruiting | USA | 0 |
NCT06008275 | Phase I | Neratinib + Ruxolitinib | Neratinib in Combination With Ruxolitinib in Patients With mTNBC | Recruiting | USA | 0 |
NCT06014502 | Phase I | IMGS-001 | Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06014658 | Phase I | MBRC-101 | Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors | Recruiting | USA | 0 |
NCT06026657 | Phase Ib/II | Gemcitabine + TGF-beta-imprinted NK cells Gemcitabine + Naxitamab + TGF-beta-imprinted NK cells | Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFbeta-i Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer | Recruiting | USA | 0 |
NCT06027268 | Phase II | Carboplatin + Gemcitabine + Pembrolizumab + Trilaciclib | Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer (ToPCourT) | Recruiting | USA | 0 |
NCT06052852 | Phase Ib/II | BDC-3042 + Pembrolizumab BDC-3042 | Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies | Recruiting | USA | 0 |
NCT06066424 | Phase I | Cyclophosphamide + Fludarabine TROP2-CAR/IL15-transduced CBNK cells Rimiducid | Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) | Recruiting | USA | 0 |
NCT06067061 | Phase Ib/II | Atezolizumab + RP1 | "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer (neoBREASTIM) | Recruiting | FRA | 0 |
NCT06084481 | Phase I | ABBV-400 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | Recruiting | USA | ISR | ESP | AUS | 4 |
NCT06084689 | Phase II | BI 907828 + Ezabenlimab | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures (EMPIRE) | Not yet recruiting | FRA | 0 |
NCT06099769 | Phase II | Capecitabine Paclitaxel Enzalutamide Enzalutamide + Mifepristone Eribulin Carboplatin | A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT06103864 | Phase III | Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Datopotamab deruxtecan + Durvalumab Datopotamab deruxtecan Carboplatin + Gemcitabine + Pembrolizumab | A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | Recruiting | USA | TUR | POL | ITA | GBR | FRA | ESP | DEU | CAN | BRA | AUS | ARG | 11 |
NCT06112379 | Phase III | Carboplatin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel Capecitabine Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel Cyclophosphamide + Doxorubicin + Pembrolizumab Cyclophosphamide + Epirubicin + Pembrolizumab Datopotamab deruxtecan + Durvalumab Cyclophosphamide + Doxorubicin + Paclitaxel Carboplatin + Paclitaxel + Pembrolizumab | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | Recruiting | USA | TUR | POL | ITA | HUN | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BGR | BEL | AUT | AUS | 10 |
NCT06136884 | Phase I | AO-252 | A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06150664 | Phase I | CTX-8371 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | Recruiting | USA | 0 |
NCT06154291 | Phase Ib/II | XON7 | FIH XON7 in Advanced/Metastatic Solid Tumors (FIPO23) | Recruiting | FRA | BEL | 0 |
NCT06162351 | Phase II | PLX038 | A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer (TOPOLOGY) | Recruiting | FRA | 0 |
NCT06167317 | Phase I | GS-0201 + Sacituzumab govitecan-hziy GS-0201 | Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors | Recruiting | USA | ISR | 0 |
NCT06171789 | Phase Ib/II | PRO1107 | PRO1107 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06175390 | Phase II | Atezolizumab + Nab-paclitaxel + Tiragolumab Atezolizumab + Tiragolumab Atezolizumab + Carboplatin + Nab-paclitaxel + Tiragolumab Atezolizumab + Cyclophosphamide + Doxorubicin + Tiragolumab | Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer (SKYLINE) | Recruiting | FRA | 0 |
NCT06193525 | Phase II | Talazoparib | FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test (FUTURE) | Recruiting | NLD | 0 |
NCT06224673 | Phase II | ARX-788 | ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer | Not yet recruiting | USA | 0 |
NCT06234098 | Phase Ib/II | AT-1965 | Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors | Recruiting | USA | 0 |
NCT06238479 | Phase I | LY4101174 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | Recruiting | USA | ESP | BEL | AUS | 1 |
NCT06238921 | Phase Ib/II | Sacituzumab govitecan-hziy + Zimberelimab Zimberelimab | Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases | Recruiting | USA | 0 |
NCT06245889 | Phase II | Cyclophosphamide Olaparib Carboplatin + Paclitaxel + Pembrolizumab Doxorubicin Capecitabine | PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC (NeoADAPT) | Recruiting | USA | 0 |
NCT06246968 | Phase I | Pembrolizumab | A Study of Pembrolizumab and Cryoablation in People With Breast Cancer | Recruiting | USA | 0 |
NCT06249048 | Phase Ib/II | Pembrolizumab + STX-001 STX-001 | Phase 1/2 Study of IT STX-001 in Patients With Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | Recruiting | USA | AUS | 0 |
NCT06264921 | Phase I | NKT3447 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06273852 | Phase I | PBA-0405 | A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors | Recruiting | USA | 0 |
NCT06318897 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab Cyclophosphamide + Doxorubicin + Pembrolizumab | Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT06324240 | Phase I | TMV vaccine Pembrolizumab + TMV vaccine Ipilimumab + TMV vaccine | Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer | Not yet recruiting | USA | 0 |
NCT06334432 | Phase Ib/II | NUV-1511 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06337630 | Phase I | M1774 + PLX038 | A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors (POP-ART) | Not yet recruiting | FRA | 0 |
NCT06342037 | Phase II | Atezolizumab + Tiragolumab Ipilimumab + Tiragolumab Atezolizumab + Ipilimumab + Tiragolumab | NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial (TONIC-3) | Recruiting | NLD | 0 |
NCT06347068 | Phase I | iC9-CAR.B7-H3 T-cells Cyclophosphamide + Fludarabine | Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells | Recruiting | USA | 0 |
NCT06351332 | Phase Ib/II | Carboplatin + Pembrolizumab + ZN-c3 | A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined With Carboplatin and Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer (ZAP-IT) | Suspended | USA | 0 |
NCT06353997 | Phase II | INBRX-106 + Pembrolizumab | Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients | Recruiting | USA | 0 |
NCT06358573 | Phase II | INT230-6 Cyclophosphamide + Doxorubicin + Pembrolizumab Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Cyclophosphamide + Epirubicin + Pembrolizumab | Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK | Recruiting | CHE | 0 |
NCT06365788 | Phase II | Abemaciclib + Bicalutamide | Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer (ABBICAR) | Recruiting | BEL | 0 |
NCT06380816 | Phase Ib/II | UCB4594 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | Recruiting | GBR | 0 |
NCT06393374 | Phase III | Pembrolizumab Pembrolizumab + SKB264 Capecitabine + Pembrolizumab | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | Recruiting | USA | POL | NOR | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 4 |
NCT06399757 | Phase Ib/II | APL-5125 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06400472 | Phase I | LY4170156 | A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 2 |
NCT06434064 | Phase II | Pegylated liposomal doxorubicin + Tamoxifen | Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer | Not yet recruiting | USA | 0 |
NCT06440005 | Phase I | AGX101 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06449222 | Phase II | BNT327 | Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy | Recruiting | USA | GBR | AUS | 0 |
NCT06451497 | Phase I | ZM008 | Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06465069 | Phase I | LY4052031 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01) | Recruiting | USA | GBR | ESP | 1 |
NCT06472583 | Phase II | Pembrolizumab | Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast Cancer (BREAST-BOOSTER) | Recruiting | POL | 0 |
NCT06492759 | Phase II | Nab-paclitaxel + Pembrolizumab Paclitaxel + Pembrolizumab Carboplatin + Gemcitabine + Pembrolizumab | High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer | Not yet recruiting | USA | 0 |
NCT06508216 | Phase Ib/II | Datopotamab deruxtecan + Durvalumab Datopotamab deruxtecan | A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer (COMPASS-TNBC) | Recruiting | FRA | 0 |
NCT06514651 | Phase I | MAQ-001 Ipilimumab + MAQ-001 | MAQ-001 in Patients With Advanced Solid Tumors | Recruiting | FRA | 0 |
NCT06526819 | Phase Ib/II | SMP-3124 | A Phase 1/2 Study of SMP-3124LP in Adults With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT06545331 | Phase I | Pembrolizumab + XB010 XB010 | Study of XB010 in Subjects With Solid Tumors | Recruiting | USA | 0 |
NCT06545682 | Phase Ib/II | Alpelisib + Pembrolizumab | Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA) | Not yet recruiting | USA | 0 |
NCT06586957 | Phase I | NKT3964 | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06631092 | Phase Ib/II | NECVAX-NEO1 | Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer | Recruiting | DEU | 0 |
NCT06634849 | Phase Ib/II | PTT-4256 | An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours. | Recruiting | AUS | 0 |
NCT06637306 | Phase I | Carboplatin + Dupilumab + Paclitaxel + Pembrolizumab | Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer | Not yet recruiting | USA | 0 |